Bio-Works Technologies AB (BIOWKS) - Net Assets
Based on the latest financial reports, Bio-Works Technologies AB (BIOWKS) has net assets worth Skr49.21 Million SEK (≈ $5.30 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr70.76 Million ≈ $7.61 Million USD) and total liabilities (Skr21.55 Million ≈ $2.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore balance sheet size of Bio-Works Technologies AB for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr49.21 Million |
| % of Total Assets | 69.54% |
| Annual Growth Rate | 8.18% |
| 5-Year Change | -54.65% |
| 10-Year Change | 108.14% |
| Growth Volatility | 114.5 |
Bio-Works Technologies AB - Net Assets Trend (2015–2025)
This chart illustrates how Bio-Works Technologies AB's net assets have evolved over time, based on quarterly financial data. Check Bio-Works Technologies AB (BIOWKS) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Bio-Works Technologies AB (2015–2025)
The table below shows the annual net assets of Bio-Works Technologies AB from 2015 to 2025. For live valuation and market cap data, see BIOWKS stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr49.21 Million ≈ $5.30 Million |
+10.37% |
| 2024-12-31 | Skr44.58 Million ≈ $4.80 Million |
+1.25% |
| 2023-12-31 | Skr44.03 Million ≈ $4.74 Million |
-34.95% |
| 2022-12-31 | Skr67.69 Million ≈ $7.28 Million |
-37.62% |
| 2021-12-31 | Skr108.51 Million ≈ $11.68 Million |
+189.69% |
| 2020-12-31 | Skr37.46 Million ≈ $4.03 Million |
-54.39% |
| 2019-12-31 | Skr82.13 Million ≈ $8.84 Million |
+33.24% |
| 2018-12-31 | Skr61.64 Million ≈ $6.63 Million |
-37.93% |
| 2017-12-31 | Skr99.32 Million ≈ $10.69 Million |
+320.10% |
| 2016-12-31 | Skr23.64 Million ≈ $2.54 Million |
+5.50% |
| 2015-12-31 | Skr22.41 Million ≈ $2.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bio-Works Technologies AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35842200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr9.82 Million | 19.96% |
| Other Components | Skr397.81 Million | 808.45% |
| Total Equity | Skr49.21 Million | 100.00% |
Bio-Works Technologies AB Competitors by Market Cap
The table below lists competitors of Bio-Works Technologies AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pyung Hwa Hldg
KO:010770
|
$37.35 Million |
|
Industrial Investment Trust Limited
NSE:IITL
|
$37.36 Million |
|
Mudajaya Group Bhd
KLSE:5085
|
$37.36 Million |
|
Communication & System Solution Public Company Limited
BK:CSS
|
$37.38 Million |
|
Kartoon Studios, Inc.
NYSE MKT:TOON
|
$37.34 Million |
|
CHUNGDAHM Learning Inc
KQ:096240
|
$37.33 Million |
|
Janover Inc. Common Stock
NASDAQ:JNVR
|
$37.31 Million |
|
FibroGen Inc
NASDAQ:FGEN
|
$37.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bio-Works Technologies AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 44,584,000 to 49,206,000, a change of 4,622,000 (10.4%).
- Net loss of 15,247,000 reduced equity.
- New share issuances of 20,263,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-15.25 Million | -30.99% |
| Share Issuances | Skr20.26 Million | +41.18% |
| Other Changes | Skr-394.00K | -0.8% |
| Total Change | Skr- | 10.37% |
Book Value vs Market Value Analysis
This analysis compares Bio-Works Technologies AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.10x to 6.54x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr1.12 | Skr3.47 | x |
| 2016-12-31 | Skr1.18 | Skr3.47 | x |
| 2017-12-31 | Skr4.94 | Skr3.47 | x |
| 2018-12-31 | Skr3.05 | Skr3.47 | x |
| 2019-12-31 | Skr2.73 | Skr3.47 | x |
| 2020-12-31 | Skr1.23 | Skr3.47 | x |
| 2021-12-31 | Skr3.48 | Skr3.47 | x |
| 2022-12-31 | Skr1.93 | Skr3.47 | x |
| 2023-12-31 | Skr1.22 | Skr3.47 | x |
| 2024-12-31 | Skr0.57 | Skr3.47 | x |
| 2025-12-31 | Skr0.53 | Skr3.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bio-Works Technologies AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.39%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.44x
- Recent ROE (-30.99%) is above the historical average (-64.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -55.16% | -801.62% | 0.06x | 1.10x | Skr-14.60 Million |
| 2016 | -72.57% | -466.60% | 0.13x | 1.19x | Skr-19.52 Million |
| 2017 | -23.82% | -478.40% | 0.05x | 1.06x | Skr-33.59 Million |
| 2018 | -61.57% | -578.32% | 0.10x | 1.09x | Skr-44.12 Million |
| 2019 | -51.28% | -755.66% | 0.06x | 1.07x | Skr-50.33 Million |
| 2020 | -118.94% | -615.83% | 0.16x | 1.21x | Skr-48.29 Million |
| 2021 | -11.93% | -59.07% | 0.18x | 1.11x | Skr-23.79 Million |
| 2022 | -66.40% | -108.79% | 0.45x | 1.35x | Skr-51.72 Million |
| 2023 | -129.04% | -129.44% | 0.71x | 1.41x | Skr-61.22 Million |
| 2024 | -83.79% | -146.70% | 0.49x | 1.18x | Skr-41.82 Million |
| 2025 | -30.99% | -24.39% | 0.88x | 1.44x | Skr-20.17 Million |
Industry Comparison
This section compares Bio-Works Technologies AB's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $741,407,000
- Average return on equity (ROE) among peers: -34.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bio-Works Technologies AB (BIOWKS) | Skr49.21 Million | -55.16% | 0.44x | $37.35 Million |
| ADDvise Group AB A (ADDV-A) | $835.00 Million | 10.78% | 3.13x | $4.23 Million |
| ADDvise Group B (ADDV-B) | $4.25 Million | -261.01% | 29.33x | $108.58 Million |
| AddLife AB (publ) (ALIF-B) | $4.29 Billion | 16.76% | 1.47x | $2.08 Billion |
| Biotage AB (BIOT) | $609.50 Million | -40.10% | 0.36x | $1.23 Billion |
| Bonesupport Holding AB (BONEX) | $727.46 Million | 18.39% | 0.21x | $1.62 Billion |
| Dynavox Group (DYVOX) | $139.50 Million | 21.36% | 7.22x | $833.82 Million |
| iZafe Group AB Series B (IZAFE-B) | $5.42 Million | -117.33% | 0.49x | $15.51 Million |
| Ortivus AB ser. A (ORTI-A) | $29.44 Million | 31.28% | 1.46x | $411.54K |
| Ortivus AB ser. B (ORTI-B) | $31.19 Million | 7.12% | 0.71x | $18.57 Million |
About Bio-Works Technologies AB
Bio-Works Technologies AB (publ), together with its subsidiaries, engages in the manufactures and sale of chromatography resins for the purification of biopharmaceuticals in Sweden. The company offers affinity and activated resin, hydrophobic interaction chromatography (HIC) resins, GoBio Mini and GoBio prepacked columns, ion exchange chromatography (IEX) resin, immobilized metal-ion affinity chr… Read more